Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics

Author:

Boyarko Ben12,Podvin Sonia1,Greenberg Barry3,Arnold Steven4,Juanes Almudena Maroto5,van der Kant Rik5,Goldstein Lawrence6,Momper Jeremiah D.1,Bang Anne7,Silverman James28,Feldman Howard H.28,Hook Vivian128ORCID

Affiliation:

1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

2. Alzheimer’s Disease Cooperative Study, School of Medicine, University of California, San Diego, La Jolla, California 92093, United States

3. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States

4. Alzheimer’s Clinical and Translational Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States

5. Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan, Amsterdam 1081 HV, The Netherlands

6. Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California 92093, United States

7. Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States

8. Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, United States

Funder

Epstein Family Research Collaboration Award

Publisher

American Chemical Society (ACS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3